- cafead   Sep 08, 2024 at 11:42: PM
via An experimental medicine from a small biotechnology company cut the risk of lung cancer progression in half when tested against the world’s most dominant immunotherapy in a clinical trial, according to study data presented Sunday at a major medical meeting.
article source
article source